On the public citation graph

Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies

https://doi.org/10.1097/mbc.0b013e328341f030
0 signed · 117 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.160.6.761openalex-snapshot
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
inferredcites →https://doi.org/10.1001/archinte.164.15.1653openalex-snapshot
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
inferredcites →https://doi.org/10.1001/jama.293.6.715openalex-snapshot
Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis
inferredcites →https://doi.org/10.1002/1097-0142(19940115)73:2<493::aid-cncr2820730240>3.0.co;2-dopenalex-snapshot
Therapy of venous thromboembolism in patients with brain metastases
inferredcites →https://doi.org/10.1007/bf01403001openalex-snapshot
Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumours
inferredcites →https://doi.org/10.1016/0248-8663(96)81247-1openalex-snapshot
Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. À propos d'une série rétrospective de 71 patients
inferredcites →https://doi.org/10.1016/j.thromres.2008.09.002openalex-snapshot
Efficacy of Low- molecular- weight- heparin versus Vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: A systematic review of randomized controlled trials
inferredcites →https://doi.org/10.1016/s0002-9378(16)32227-xopenalex-snapshot
Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy
inferredcites →https://doi.org/10.1016/s0140-6736(98)05095-8openalex-snapshot
Involvement of platelets in tumour angiogenesis?
inferredcites →https://doi.org/10.1016/s1470-2045(08)70149-9openalex-snapshot
Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1056/nejmoa025313openalex-snapshot
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
inferredcites →https://doi.org/10.1093/annonc/mdn110openalex-snapshot
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations
inferredcites →https://doi.org/10.1093/annonc/mdp167openalex-snapshot
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations
inferredcites →https://doi.org/10.1097/00005792-199909000-00001openalex-snapshot
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
inferredcites →https://doi.org/10.1097/jto.0b013e31811ea275openalex-snapshot
High Risk of Deep Vein Thrombosis in Patients with Non-small Cell Lung Cancer: A Cohort Study of 493 Patients
inferredcites →https://doi.org/10.1111/j.1538-7836.2004.00853.xopenalex-snapshot
Fixed‐dose low‐molecular‐weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study
inferredcites →https://doi.org/10.1111/j.1538-7836.2004.00928.xopenalex-snapshot
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma
inferredcites →https://doi.org/10.1111/j.1538-7836.2005.01467.xopenalex-snapshot
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment
inferredcites →https://doi.org/10.1111/j.1538-7836.2006.01804.xopenalex-snapshot
Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2277openalex-snapshot
A Functional Role for Hemostasis in Early Cancer Development
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-0445openalex-snapshot
Plasma Coagulation Markers in Patients with Solid Tumors and Venous Thromboembolic Disease Receiving Oral Anticoagulation Therapy
inferredcites →https://doi.org/10.1159/000055014openalex-snapshot
Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement
inferredcites →https://doi.org/10.1160/th06-01-0009openalex-snapshot
Recurrent venous thromboembolism under anticoagulant therapy: A high risk in adenocarcinoma?
inferredcites →https://doi.org/10.1160/th08-02-0125openalex-snapshot
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism
inferredcites →https://doi.org/10.1182/blood-2002-01-0108openalex-snapshot
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
inferredcites →https://doi.org/10.1182/blood.v93.11.3811openalex-snapshot
Vascular Endothelial Cell Growth Factor–Induced Tissue Factor Expression in Endothelial Cells Is Mediated by EGR-1
inferredcites →https://doi.org/10.1200/jco.2007.14.1283openalex-snapshot
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4133624openalex-extracted
inferred← citeshttps://doi.org/10.1002/ajh.23128openalex-snapshot
Predicting the risk of venous thromboembolism recurrence
inferred← citeshttps://doi.org/10.1002/ajh.25459openalex-snapshot
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
inferred← citeshttps://doi.org/10.1002/rth2.12176openalex-snapshot
Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
inferred← citeshttps://doi.org/10.1007/978-1-4614-9560-4_11openalex-snapshot
The Excessively Clotting Cancer Patient
inferred← citeshttps://doi.org/10.1007/s00520-013-1792-9openalex-snapshot
Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score
inferred← citeshttps://doi.org/10.1007/s00520-019-05150-zopenalex-snapshot
Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model
inferred← citeshttps://doi.org/10.1007/s11239-015-1311-6openalex-snapshot
The epidemiology of venous thromboembolism
inferred← citeshttps://doi.org/10.1007/s11239-020-02040-8openalex-snapshot
PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00020-2openalex-snapshot
Clinical Presentation and Prognostic Factors in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-1-4557-2296-9.00014-2openalex-snapshot
Thrombophilia
inferred← citeshttps://doi.org/10.1016/j.apjon.2022.100128openalex-snapshot
Development and validation of a machine learning model to predict venous thromboembolism among hospitalized cancer patients
inferred← citeshttps://doi.org/10.1016/j.ejca.2022.01.023openalex-snapshot
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study
inferred← citeshttps://doi.org/10.1016/j.ejim.2016.08.001openalex-snapshot
External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis
inferred← citeshttps://doi.org/10.1016/j.jtha.2023.04.010openalex-snapshot
Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study
inferred← citeshttps://doi.org/10.1016/j.mcna.2025.01.004openalex-snapshot
Risk Factors and Management of Cancer-Associated Thrombosis
inferred← citeshttps://doi.org/10.1016/j.medcli.2012.06.023openalex-snapshot
Riesgo de recurrencia en la enfermedad tromboembólica venosa tras suspender la anticoagulación
inferred← citeshttps://doi.org/10.1016/j.rpth.2023.100115openalex-snapshot
Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy
inferred← citeshttps://doi.org/10.1016/j.semerg.2023.102030openalex-snapshot
Recomendaciones sobre enfermedad tromboembólica venosa en procesos oncológicos. Una visión desde la medicina de familia
inferred← citeshttps://doi.org/10.1016/j.thromres.2013.01.025openalex-snapshot
The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE
inferred← citeshttps://doi.org/10.1016/j.thromres.2014.10.030openalex-snapshot
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.08.002openalex-snapshot
Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.11.033openalex-snapshot
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs
inferred← citeshttps://doi.org/10.1016/j.thromres.2016.03.006openalex-snapshot
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
inferred← citeshttps://doi.org/10.1016/j.thromres.2017.12.019openalex-snapshot
Management of recurrent venous thromboembolism in patients with cancer: A review
inferred← citeshttps://doi.org/10.1016/j.thromres.2019.07.005openalex-snapshot
The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism
inferred← citeshttps://doi.org/10.1016/j.thromres.2022.11.005openalex-snapshot
Influence of Primary Cancer Site on Clinical Outcomes of Anticoagulation for Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.06.015openalex-snapshot
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
inferred← citeshttps://doi.org/10.1016/j.thromres.2024.109228openalex-snapshot
Relevance of recurrent venous thromboembolism according to location of metastasis in patients with cancer-associated thrombosis. A cohort study
inferred← citeshttps://doi.org/10.1016/j.tru.2021.100080openalex-snapshot
Risk assessment for recurrent venous thromboembolism in patients with cancer
inferred← citeshttps://doi.org/10.1016/s0025-7753(15)30013-0openalex-snapshot
Tratamiento a largo plazo con una heparina de bajo peso molecular subcutánea comparado con un antagonista de la vitamina K: subanálisis de pacientes con cáncer
inferred← citeshttps://doi.org/10.1016/s0049-3848(14)50003-5openalex-snapshot
Predicting recurrent venous thromboembolism in cancer: is it possible?
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30106-2openalex-snapshot
Predictors of recurrent venous thromboembolism and bleeding on anticoagulation
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30108-6openalex-snapshot
Primary prophylaxis of VTE in cancer outpatients
inferred← citeshttps://doi.org/10.1017/cbo9780511977633.030openalex-snapshot
Acute complications
inferred← citeshttps://doi.org/10.1038/nrcardio.2015.83openalex-snapshot
Epidemiology of venous thromboembolism
inferred← citeshttps://doi.org/10.1038/s41598-017-03596-xopenalex-snapshot
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
inferred← citeshttps://doi.org/10.1055/a-2535-7400openalex-snapshot
Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type
inferred← citeshttps://doi.org/10.1055/s-0034-1370770openalex-snapshot
Risk Assessment for Thrombosis in Cancer
inferred← citeshttps://doi.org/10.1055/s-0038-1641586openalex-snapshot
Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations
inferred← citeshttps://doi.org/10.1055/s-0041-1736037openalex-snapshot
Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives
inferred← citeshttps://doi.org/10.1080/03007995.2021.1932448openalex-snapshot
Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer
inferred← citeshttps://doi.org/10.1080/07357907.2017.1340480openalex-snapshot
Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism
inferred← citeshttps://doi.org/10.1080/17474086.2016.1194750openalex-snapshot
A review of the venous thrombotic issues associated with multiple myeloma
inferred← citeshttps://doi.org/10.1080/17843286.2020.1731661openalex-snapshot
Lemierre’s syndrome in adulthood, a case report and systematic review
inferred← citeshttps://doi.org/10.1093/jjco/hyaa112openalex-snapshot
Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry
inferred← citeshttps://doi.org/10.1097/mbc.0000000000000193openalex-snapshot
The humanistic and economic burden of venous thromboembolism in cancer patients
inferred← citeshttps://doi.org/10.1111/iju.12056openalex-snapshot
Urinary retention in a female patient caused by a urethral venous thrombus with massive edema
inferred← citeshttps://doi.org/10.1111/jth.12192openalex-snapshot
Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis
inferred← citeshttps://doi.org/10.1160/th-17-06-0382openalex-snapshot
Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice
inferred← citeshttps://doi.org/10.1161/circulationaha.111.051920openalex-snapshot
Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1177/0003319715614945openalex-snapshot
Venous Thromboembolism in Patients Diagnosed With Lung Cancer
inferred← citeshttps://doi.org/10.1177/1076029617696581openalex-snapshot
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1177/1078155220984371openalex-snapshot
Clinical controversies in the treatment of cancer-associated venous thromboembolism
inferred← citeshttps://doi.org/10.1177/2040620711422590openalex-snapshot
Prevention and treatment of venous thromboembolism in patients with cancer
inferred← citeshttps://doi.org/10.1182/asheducation-2016.1.196openalex-snapshot
Thrombosis in the setting of cancer
inferred← citeshttps://doi.org/10.1182/asheducation-2017.1.128openalex-snapshot
When can we stop anticoagulation in patients with cancer-associated thrombosis?
inferred← citeshttps://doi.org/10.1182/blood-2014-01-549733openalex-snapshot
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
inferred← citeshttps://doi.org/10.1182/blood-2017-05-787929openalex-snapshot
When can we stop anticoagulation in patients with cancer-associated thrombosis?
inferred← citeshttps://doi.org/10.1182/blood.v116.21.475.475openalex-snapshot
Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1182/blood.v126.23.2321.2321openalex-snapshot
Thromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review
inferred← citeshttps://doi.org/10.1186/1471-2407-13-76openalex-snapshot
Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer
inferred← citeshttps://doi.org/10.1200/jco.18.01977openalex-snapshot
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study
inferred← citeshttps://doi.org/10.1200/jco.2014.56.5184openalex-snapshot
How Long Is Long Enough? Extended Anticoagulation for the Treatment of Cancer-Associated Deep Vein Thrombosis
inferred← citeshttps://doi.org/10.1371/journal.pone.0114445openalex-snapshot
Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
inferred← citeshttps://doi.org/10.1517/13543784.2011.625008openalex-snapshot
Low molecular weight heparins in the treatment of lung cancer
inferred← citeshttps://doi.org/10.1590/s0100-879x2011007500166openalex-snapshot
Epidemiology of recurrent venous thrombosis
inferred← citeshttps://doi.org/10.1590/s0102-67202012000400002openalex-snapshot
Prevenção do tromboembolismo na cirurgia do câncer do aparelho digestivo
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2016.0057openalex-snapshot
Implantable port thrombosis in cancer patients: a monocentric experience
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1496380/v1openalex-snapshot
Using machine learning to evaluate the risk of venous thromboembolism for hospitalized cancer patients
inferred← citeshttps://doi.org/10.21873/anticanres.13954openalex-snapshot
Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental
inferred← citeshttps://doi.org/10.2217/bmt.15.10openalex-snapshot
Management of Chemotherapy-Induced Thromboembolism in Breast Cancer
inferred← citeshttps://doi.org/10.2217/fmeb2013.13.151openalex-snapshot
Epidemiology and prevention of deep vein thrombosis
inferred← citeshttps://doi.org/10.23736/s0026-4806.19.06026-9openalex-snapshot
Treatment of venous thromboembolism with tinzaparin in oncological patients
inferred← citeshttps://doi.org/10.23736/s0031-0808.20.04133-6openalex-snapshot
Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents
inferred← citeshttps://doi.org/10.2450/2018.0143-18openalex-snapshot
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
inferred← citeshttps://doi.org/10.2512/jspm.6.233openalex-snapshot
Efficacy and safety of peripherally inserted central catheters in patients receiving chemotherapy
inferred← citeshttps://doi.org/10.3238/arztebl.2019.0031openalex-snapshot
Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism
inferred← citeshttps://doi.org/10.32474/oajom.2019.03.000160openalex-snapshot
Recurrent Ischemic Stroke as a First Manifestation of Poorly Differentiated Carcinoma (PDC) of Unknown Etiology
inferred← citeshttps://doi.org/10.32474/oajom.3.2openalex-snapshot
inferred← citeshttps://doi.org/10.3324/haematol.2024.286152openalex-snapshot
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding
inferred← citeshttps://doi.org/10.3384/diss.diva-159085openalex-snapshot
Vascular access in cancer patients – clinical implications
inferred← citeshttps://doi.org/10.3389/fonc.2025.1619554openalex-snapshot
Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies
inferred← citeshttps://doi.org/10.3390/ijerph18020394openalex-snapshot
Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study
inferred← citeshttps://doi.org/10.3390/jcm9092876openalex-snapshot
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
inferred← citeshttps://doi.org/10.34626/8ghc-qz23openalex-snapshot
Estados Trombofílicos no doente com cancro. Incidência, profilaxia, tratamento e perpetivas futuras
inferred← citeshttps://doi.org/10.36469/9822openalex-snapshot
Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort
inferred← citeshttps://doi.org/10.3892/ol.2015.3304openalex-snapshot
Low local blood perfusion, high white blood cell and high platelet count are associated with primary tumor growth and lung metastasis in a 4T1 mouse breast cancer metastasis model
inferred← citeshttps://doi.org/10.4081/btvb.2024.114openalex-snapshot
Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review
inferred← citeshttps://doi.org/10.70675/4893255az220cz4e47z8833ze45283a937a4openalex-snapshot
Development and validation of risk scores in vascular diseases
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.